Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5851_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Foreword
- •Foreword
- •Contents of Volume I
- •Contents of Volume II
- •Contributors
- •1.1 Introduction
- •1.4.3 Acute Stroke
- •1.4.4 CNS Infection
- •1.4.1 Sepsis
- •1.4.2 Acute Encephalopathy
- •1.4.5 Severe Community-Acquired Pneumonia
- •1.4.6 Nosocomial Pneumonia
- •1.4.7 Pulmonary Edema
- •1.4.8 Fever
- •References
- •2.1 Introduction
- •2.4 ECG Nomenclature
- •2.4.1 P Wave
- •2.4.2 PR Interval
- •2.4.3 QRS Complex
- •2.4.4 J Point
- •2.4.5 ST Segment
- •2.4.6 T Wave
- •2.4.7 QT Interval
- •2.4.8 U Wave
- •2.4.9 RR Interval
- •2.5.1 P Wave
- •2.5.1.1 Atrial Arrhythmias
- •Atrial Fibrillation
- •Atrial Flutter
- •Atrial Tachycardia
- •Multifocal Atrial Tachycardia
- •2.5.1.2 Interatrial Blocks
- •Intermittent Interatrial Block (I-IAB)
- •Advanced Interatrial Block (A-IAB)
- •2.5.2 P-QRS Ratio
- •2.5.2.1 Shortened P-QRS Ratio
- •Wolff-Parkinson-White Syndrome (WPW)
- •Junctional Rhythm
- •Atrioventricular Nodal Reentrant Tachycardia (AVNRT)
- •2.5.2.3 Prolonged P-QRS Ratio
- •2.5.3 PR Interval
- •2.5.3.1 Shortened PR Interval
- •2.5.3.2 Prolonged PR Interval
- •2.5.3.3 Second-Degree AV Block
- •Advanced AV Block
- •Third-Degree AV Block (Complete Heart Block)
- •2.5.4 PR Segment
- •2.5.4.1 PR-Segment Elevation
- •2.5.4.2 PR-Segment Depression
- •Acute Pericarditis
- •Acute Myocardial Ischemia
- •2.5.5 Q Waves
- •2.5.6 QRS Complex
- •2.5.6.1 Heart Rate
- •2.5.7 QT Interval
- •2.5.8 ST Segment
- •2.5.8.1 ST-Segment Depression
- •2.5.8.2 ST-Segment Elevation
- •2.5.9 T Waves
- •2.5.9.1 Inverted T Wave
- •2.5.9.2 Flattened T Wave
- •2.5.9.3 Peaked T Wave
- •References
- •Further Reading
- •3.1 Introduction
- •3.2.2 Nasogastric Tube
- •3.2.3 Central Venous Catheters
- •3.2.4 Cardiac Devices
- •3.2.5 Arterial Catheters
- •3.3 Cardiopulmonary Abnormalities
- •3.3.1 Pulmonary Edema
- •3.3.2 Acute Respiratory Distress Syndrome
- •3.3.3 Atelectasis
- •3.3.4 Aspiration
- •3.3.5 Pneumonia
- •References
- •4.1 Introduction
- •4.5 Modes of Mechanical Ventilation
- •4.5.1 Volume Control Ventilation
- •4.5.2 Pressure Control Ventilation
- •4.5.3 Pressure Support Ventilation
- •4.6 Patient-Ventilator Interactions
- •4.6.1 Trigger Dyssynchrony
- •4.6.2 Flow Dyssynchrony
- •4.6.3 Cycle Dyssynchrony
- •4.9.1 Acute Respiratory Distress Syndrome
- •4.9.2 Severe Asthma Exacerbation
- •4.11 Summary
- •5.10 Neuromuscular Blockade
- •References
- •5.1 Introduction
- •5.3 Pathobiology
- •5.4 ARDS Phenotypes
- •5.5 Lung-Protective Ventilation
- •5.6 Positive End-Expiratory Pressure
- •5.7 Conservative Fluid Management
- •5.8 Moderate-to-Severe ARDS
- •5.9 Prone Positioning
- •5.11 Corticosteroids
- •5.12 Inhaled Pulmonary Vasodilators
- •5.13 Veno-Venous Extracorporeal Membrane Oxygenation
- •5.14 Survivorship
- •References
- •6.1 Introduction/Epidemiology
- •6.2 Physiology
- •6.2.2 Physiology During COPD Exacerbation
- •6.4 Pharmacologic Treatment
- •6.4.1 Bronchodilators
- •6.4.1.1 Mechanism
- •6.4.2 Glucocorticoid Therapy
- •6.4.2.1 Mechanism
- •6.4.2.4 Duration
- •6.4.3 Antimicrobials
- •6.4.3.1 Antibiotic Patient Selection
- •6.4.4.1 Nonpharmacologic Interventions
- •6.4.4.2 Opioids
- •6.4.4.3 Benzodiazepines
- •6.4.4.4 Dexmedetomidine
- •6.4.4.5 Ketamine
- •6.4.5 Adjunctive Therapies
- •6.4.5.1 Magnesium
- •6.4.5.3 Vitamin D
- •6.4.5.4 Venous Thromboembolism Prophylaxis
- •6.4.5.5 Smoking Cessation
- •6.4.5.6 Bowel Regimen
- •6.4.5.7 Mucolytics
- •6.4.5.8 Nutrition
- •6.4.5.9 Post-Discharge Adjuncts
- •6.5 ICU-Level Interventions
- •6.5.1 Noninvasive Positive-Pressure Ventilation
- •6.5.2 High-Flow Nasal Canula
- •6.5.3 Invasive Mechanical Ventilation
- •6.6 Conclusion
- •References
- •7.1 Introduction
- •7.1.1 What Is Asthma?
- •7.2 Diagnosis
- •7.2.1 Physical Examination
- •7.2.2 Laboratory Data
- •7.2.3 Radiographic Findings
- •7.3.1 Standard-of-Care Therapy
- •7.3.3 Potential Adjunctive Therapies
- •7.3.3.1 Inhaled Corticosteroids (ICSs)
- •7.3.3.4 Intravenous (IV) Aminophylline
- •7.3.3.5 Intravenous (IV) Beta2-Agonists
- •7.3.3.6 Leukotriene Antagonists (LTRAs)
- •7.3.3.7 Intramuscular (IM) or IV Epinephrine
- •7.3.3.8 Inhaled Anesthetics
- •7.3.3.9 Inhaled Helium-Oxygen (Heliox)
- •7.3.3.10 Intravenous Ketamine
- •7.3.4.1 Subcutaneous (SC) Biologics
- •7.4.1 Noninvasive Ventilation (NIV)
- •7.4.2 Invasive Mechanical Ventilation (IMV)
- •7.6.1 Outpatient Follow-Up
- •7.7 Summary
- •References
- •8.1 Introduction
- •8.1.3.2 Anatomic Location
- •8.1.3.3 Chronicity
- •8.1.4 Clinical Presentation
- •8.1.4.1 Symptoms
- •8.1.4.2 Physician Examination
- •8.1.4.3 Cardiopulmonary Compromise
- •8.2.1.1 Clinical Pretest/Scores
- •8.2.1.2 D-Dimer-Level Interpretations
- •8.2.2 Computed Tomography Pulmonary Angiography (CTPA)
- •8.2.3 Mortality Risk Assessment
- •8.2.3.1 PE Severity Index Score
- •8.2.3.2 Prognostic Indicators
- •8.3.2 High-Risk PE
- •8.4 Systemic Thrombolytic Therapy
- •8.4.1.1 High-Risk PE
- •8.4.1.2 Intermediate-Risk PE
- •8.4.1.3 Cardiac Arrest
- •8.5.2 Percutaneous Mechanical Interventions
- •8.5.2.2 Catheter-Directed Thrombolysis
- •8.5.3 Surgical Embolectomy
- •8.5.4 Mechanical Circulatory Support
- •8.6.1 PE Response Team (PERT)
- •8.6.3.1 Renal Dysfunction
- •8.6.3.4 Cancer
- •8.6.3.5 Treatment Failure
- •8.7 Conclusion
- •References
- •9.1.2 ECMO Outcomes
- •9.2 ECMO During Cardiopulmonary Resuscitation (eCPR)
- •9.2.1 Extracorporeal Carbon Dioxide Removal
- •9.3 ECMO Management
- •9.3.3 Fluid Management
- •9.4.1 Coagulation Changes
- •9.4.2 Transfusion Thresholds
- •9.4.3.1 Heparin
- •9.4.3.2 Direct Thrombin Inhibitors
- •9.4.4 Monitoring Anticoagulation
- •9.6.2.1 Opioids
- •9.6.2.2 Ketamine
- •9.6.2.3 Propofol
- •9.6.2.4 Benzodiazepines
- •9.6.2.5 Dexmedetomidine
- •9.7.1 Aminoglycosides
- •9.7.2 Beta-Lactams
- •9.7.4 Antifungals
- •9.9 Other Complications
- •9.9.1 Bleeding
- •9.9.2 Thrombosis
- •9.9.3 Neurologic
- •9.10 Conclusion
- •References
- •10.1 Type 1–5 Myocardial Infarctions
- •10.2 Acute Coronary Syndrome (Type 1 MI)
- •10.3 Clinical Presentation/Evaluation
- •10.4 Non-pharmacologic Therapy
- •10.5 Pharmacologic Therapy
- •10.5.1 Fibrinolytics
- •10.5.2 Anticoagulants
- •10.5.2.1 Heparins
- •10.5.2.2 Direct Thrombin Inhibitors
- •10.5.3 Antiplatelets
- •10.5.3.1 Aspirin
- •10.5.3.2 P2Y12 Inhibitors
- •Clopidogrel
- •Prasugrel
- •Ticagrelor
- •10.5.3.3 Glycoprotein IIb/IIIa Receptor Inhibitors
- •10.5.3.4 Cangrelor
- •10.7 Long-Term Management
- •10.7.1 High Bleed Risk (HBR)
- •10.7.2 Statins
- •10.7.3 Beta-Blockers
- •10.7.5 Mineralocorticoid Receptor Antagonists
- •References
- •11.1 Introduction
- •11.2.2 What is Ejection Fraction?
- •11.4 Understanding Blood Pressure
- •11.5 Preload vs. Afterload
- •11.6 Acute Decompensated Heart Failure
- •11.6.2 Etiology
- •11.8 Treating Volume Overload
- •11.8.1 Loop Diuretics
- •11.9 Intravenous Vasodilators
- •11.10 Cardiogenic Shock
- •11.10.1 Inotrope Clinical Pearl
- •11.12 Digoxin
- •11.12.3 Loading Dose
- •11.12.4 Maintenance Dosing
- •11.12.5 Monitoring
- •11.12.7 Distribution
- •11.12.8 Drug-Drug Interactions
- •11.12.9 Digoxin Toxicity
- •11.13 ADHF Clinical Pearls
- •11.13.3 Avoid Phenylephrine
- •11.13.4 Use Mean Arterial Pressure (MAP)
- •11.14 Guideline-Directed Medical Therapy
- •11.15 Venous Thromboembolism (VTE) Prophylaxis
- •11.16 Conclusion
- •References
- •12.1 Introduction
- •12.3 Diagnostic Findings
- •12.4.1 Oxygen Therapy
- •12.4.2 Pharmacological Management
- •12.4.3 Mechanical Circulatory Support (MCS)
- •12.5 Pulmonary Hypertension
- •12.6 The Pharmacist’s Role
- •12.7 Conclusion
- •References
- •13.1 Introduction
- •13.2 Atrial Arrhythmias
- •13.2.2 Atrioventricular Blocks
- •13.2.3 Atrial Fibrillation
- •13.2.3.2 Anticoagulation
- •13.2.3.3 Rate vs. Rhythm Control
- •13.2.4 Atrial Flutter
- •13.2.5 Supraventricular Tachycardia (SVT)
- •13.3 Ventricular Arrhythmias
- •13.3.1 Premature Ventricular Complexes
- •13.3.2 Ventricular Tachycardia
- •13.3.2.1 Torsades de Pointes
- •13.3.3 Ventricular Fibrillation
- •13.3.4 Ventricular Arrhythmia Treatment Strategies
- •13.3.4.1 ICD Implantation
- •13.3.4.2 Pharmacologic Treatments
- •13.3.4.3 Catheter Ablation
- •13.4 Conclusion
- •References
- •14.1 Introduction
- •14.3.2 Laboratory Assessment
- •14.3.3 Imaging
- •14.3.4 Invasive Hemodynamic Monitoring
- •14.4.1 Distributive
- •14.4.2 Cardiogenic
- •14.4.3 Hypovolemic
- •14.4.4 Obstructive
- •14.5 Management
- •14.6 Conclusion
- •References
- •15.1 Background
- •15.2 Diagnosis
- •15.3 Management
- •References
- •16.1 Introduction
- •16.3 Hemodynamics
- •16.5 Pharmacological Management
- •16.5.1 Hyperosmolar Therapy
- •16.5.3 Barbiturate Coma
- •16.6 Nonpharmacological Treatments
- •16.6.2 Temperature Management
- •16.6.3 Prophylactic Hypothermia
- •16.7 Adjunct Therapies
- •16.7.2 Venous Thromboembolism (VTE) Prophylaxis
- •16.7.3 Antibiotic Prophylaxis
- •16.7.4 Stress Ulcer Prophylaxis (SUP)
- •16.7.5 Tranexamic Acid
- •16.7.6 Glucose Targets
- •16.7.7 Steroids
- •16.8 Complications
- •16.8.1 Paroxysmal Sympathetic Hyperactivity
- •16.8.3 Central Fever
- •16.8.4.1 Diabetes Insipidus
- •16.8.4.3 Cerebral Salt Wasting Syndrome
- •16.9 Conclusion
- •References
- •17.1 Introductory Case
- •17.2 Introduction
- •17.4 Pathophysiology
- •17.5 Acute Therapies
- •17.5.1 Thrombolytic Therapy
- •17.5.2 Thrombectomy
- •17.5.3 Blood Pressure Management
- •17.5.4 Acute Anticoagulation
- •17.5.5 Antiplatelet Therapy
- •17.6 Early Complications
- •17.6.1 Hemorrhagic Conversion
- •17.6.2 Angioedema
- •17.6.3 Malignant Cerebral Edema
- •17.7 Secondary Prevention
- •References
- •18.1 Introduction
- •18.4 Therapeutic Drug Monitoring
- •18.5 Adverse Drug Effects
- •18.7 Anti-seizure Medications
- •18.7.1 Available Parenteral Preparations
- •18.7.1.1 Benzodiazepines: GABAA Receptor Activation
- •18.7.1.2 Other GABAergic Therapies
- •Barbiturates: GABAergic
- •Phenobarbital
- •Pentobarbital Infusion
- •Propofol Infusion: GABAergic
- •18.7.1.3 Second-Line Non-anesthetic ASMs
- •Levetiracetam: Synaptic Vesicle Protein 2A Binding

The Pharmacist’s
Expanded Role in
Critical Care Medicine
A Comprehensive Guide for
Practitioners and Trainees
Yasir Alzaidi
Mohamed Abdelzaher Gebily
Editors
Forewords by
Jean-Louis Vincent
Bradford D. Winters
Judith Jacobi
123

The Pharmacist’s Expanded Role in Critical
Care Medicine

Yasir Alzaidi • Mohamed Abdelzaher Gebily
Editors
The Pharmacist’s Expanded
Role in Critical Care
Medicine
A Comprehensive Guide forPractitioners
andTrainees

Editors
Yasir Alzaidi
Department of Pharmacy
Al Hada Armed Forces Hospital
Taif, Saudi Arabia
Mohamed Abdelzaher Gebily
Department of Intensive Care
Al Hada Armed Forces Hospital
Taif, Saudi Arabia
ISBN 978-3-031-77334-1 ISBN 978-3-031-77335-8 (eBook)
https://doi.org/10.1007/978-3-031-77335-8
© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland
AG 2025
This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether
the whole or part of the material is concerned, specically the rights of translation, reprinting, reuse of
illustrations, recitation, broadcasting, reproduction on microlms or in any other physical way, and
transmission or information storage and retrieval, electronic adaptation, computer software, or by similar
or dissimilar methodology now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication
does not imply, even in the absence of a specic statement, that such names are exempt from the relevant
protective laws and regulations and therefore free for general use.
The publisher, the authors and the editors are safe to assume that the advice and information in this book
are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the
editors give a warranty, expressed or implied, with respect to the material contained herein or for any
errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional
claims in published maps and institutional afliations.
This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
If disposing of this product, please recycle the paper.

Foreword
The role of the pharmacist in critical care medicine has become increasingly important and multifaceted in recent years. Critically ill patients are highly heterogeneous
in terms of age, underlying comorbidities, prehospital medication usage, admission
diagnoses, allergies, concurrent organ replacement therapies, and so on. The acute
nature of their illness means that their condition and hence management can change
rapidly during their stay, and the disease severity means that many will require multiple medications during, and after, their ICU stay. As integral members of the critical care team, ICU pharmacists have the essential training and knowledge to ensure
that prescriptions are individualized such that each patient receives the best drug for
them, at the optimal dose, with minimal adverse effects throughout their ICU and
hospital stays. ICU pharmacists are also pivotal to successful antimicrobial stewardship programs and accurate interpretation of therapeutic drug monitoring, and their
involvement in the diagnostic process and in identifying diagnostic, as well as medication, errors is increasingly encouraged.
Despite their increased presence on our ICUs and involvement in patient management, there are few textbooks aimed specically at critical care pharmacists, particularly in terms of their potential role in diagnosis. Recognizing this important gap, the
editors of this comprehensive book have gathered together 55 chapters that provide
an overview of core aspects of critical care patient management from the pharmacist’s perspective. The chapters, written by an international team of more than 100
experts, provide an important update on the physiological and pathological mechanisms of key areas of critical illness and the diagnostic and therapeutic approaches
to these conditions for the pharmacist. There are chapters focusing on specic diseases or conditions, including shock, acute liver failure, acute kidney injury, delirium, and acute pulmonary embolism; chapters on interpretation of diagnostic tests,
such as radiology and electrocardiography; chapters on therapeutic interventions,
including mechanical ventilation, intravenous uids, renal replacement therapy,
ECMO, nutrition, and blood transfusion; and chapters on specic groups of ICU
patients, including obstetric, oncology, transplant, and burn patients. Two of the
chapters, on the approach to clinical reasoning in critical care and sustainable pharmacy practice in the ICU, are unique chapters to pharmacy education and training.
v

vi
Foreword
Providing an up-to-date overview of topics related to critical care and emphasizing the importance of correct diagnosis in providing appropriate and optimal treatment, this collection will help prepare ICU pharmacists for their multifaceted
responsibilities as members of the ICU team, including an expanded role in limiting
misdiagnosis. This book will serve as a useful resource for all pharmacists involved
in the management of critically ill patients, whatever their level of experience and
training, and I congratulate the editors on their achievement.
Jean-LouisVincentUniversité Libre de Bruxelles
Brussels, Belgium
Department of Intensive Care
Erasme University Hospital
Brussels, Belgium

Foreword
The critical care environment, encompassing the intensive care unit as well as critical care outreach to intermediate care units and the general ward in the form of rapid
response systems and medical emergency teams, is tremendously challenging clinically and in terms of patient safety and quality. Pharmacists have a crucial and
central role in ensuring the best quality of clinical care and promoting patient safety.
Medication errors in these high-stress environments and situations are one of the
most common patient safety and quality concerns, and pharmacists are the experts
that intensivists, nurses, and respiratory therapists turn to for help in avoiding these
types of medical errors. In addition, critically ill patients often receive a large number of medications and have deranged physiology and pharmacodynamics and pharmacokinetics that create a complicated milieu that needs to be carefully balanced to
avoid complications and optimize outcome. Pharmacists enhance the quality of care
by using their knowledge and education to guide the care team in making the best
pharmacological choices for each patient. They also assist prescribers in making the
most cost-effective choices, something that is crucial in the current healthcare environment where costs are a major concern. Their role, however, goes well beyond
optimization of drug therapy and prevention of medication errors. In the ICU, pharmacists’ role is increasingly underscored in ensuring precise diagnoses, a cornerstone for effective drug therapy. Notably, diagnostic errors in the ICU pose
substantial concerns, as evidenced by a systematic review led by Winters et al.
(2012), revealing alarming rates of errors, including those with lethal implications.
Actively engaging in diagnostic deliberations, pharmacists leverage their extensive
knowledge in pharmacotherapy to offer invaluable insights that either corroborate
or challenge diagnoses. This interdisciplinary synergy is pivotal in aligning treatments with accurate diagnoses, thereby elevating the caliber of patient care.
This book aims to foster interdisciplinary team collaboration that cultivates a
culture of safety and precision in patient care, essential for averting diagnostic pitfalls and ensuring therapeutic efcacy. The book contains chapters that enhance
diagnostic reasoning and prevent diagnostic errors. In addition, the book provides a
comprehensive state-of-the-art review of all topics related to critical care authored
by experts from prestigious institutions. I congratulate Dr. Alzaidi on this
vii

viii
Foreword
achievement, and I hope that this book will inform administrators and providers as
to the nancial, safety, and quality benets that pharmacists provide in the critical
care environment and spur hospitals to make the central role of the pharmacist in the
management of critically ill patients a universal reality that all intensive care units
and their patients can enjoy and benet from.
Department of Anesthesiology and Critical
Care Medicine, Co-Director of the
Johns Hopkins Hospital Surgical ICUs
and the Bayview Medical Center Surgical
and Burn ICUs, Core Faculty Armstrong Institute
for Patient Safety and Quality
The Johns Hopkins University School
of Medicine,
Baltimore, MD, USA
BradfordD.Winters

Foreword
The history of critical care pharmacists extends beyond 50years, but the growth of
services, personnel, research, and magnitude of impact has been exponential. Early
in my critical care practice, the focus was on the recognition of our contributions
and justication of our roles. While we created a ripple initially, the effect has magnied into a tidal wave of highly trained and engaged pharmacists providing comprehensive medication management for patients in a myriad of settings and with
complex clinical problems and management programs.
Key milestones in the development of critical care pharmacists include organization as sections within professional organizations, description of our practice and
services, Board Certication in 2012, expansion of critical care residency training
programs, guideline and position paper authorship, leadership in inuential multiprofessional organizations with active participation in committees, and ongoing
documentation of our clinical and economic impact. While individuals are sometimes recognized, it is the inuence of the whole that continues to build to tsunami levels.
This text provides a comprehensive view into the broad and expanding world of
critical care pharmacy and pharmacologic challenges. I am consistently impressed
and amazed by the dedication, knowledge, and creativity of my colleagues worldwide. We have come a long way from gentamicin dosing as a primary focus! The
author list of this text includes an amazing group of contributors, and I congratulate
them and the editors for comprehensive topics that illustrate current and future roles.
Importantly, the scope of contributions illustrates that we always have new areas
to explore, new services to provide, and new growth opportunities. We will be challenged with tools like articial intelligence or other new technologies, but I have
faith that they will be harnessed to improve efciency and processes. The ultimate
reward will be the steadily improving care we provide, in conjunction with our critical care colleagues and teams.
At the same time, I feel that the million little things we do as pharmacists—consistently, every day (or night)—are the most important drivers for optimal patient
outcomes (rather than the new and ashy). Additionally, the ability to admit when
we are wrong (like my initial resistance to assuming responsibility for a valid
ix

x
Foreword
medication history) is an important component of our growth as individuals and a
professional.
Another important consideration is that while critical care pharmacists excel as
entrepreneurs and love to develop new skills and services, a signicant opportunity
remains to ensure a consistent and standardized scope of practice that describes our
foundation and commonalities of practice as a team of pharmacists. We need to
ensure that other practitioners can understand and expect specic services, at a minimum. Other standardized tools that allow us to measure outcomes based on the
severity of illness or complexity of therapeutics and care will strengthen our ability
to document our impact as essential critical care team members.
The roles are limitless, and the tide is moving forward quickly.
Lebanon, IN, USA JudithJacobi
Соседние файлы в папке Библиотека им академика М.И. Перельмана
